Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19).
Valentina O Puntmann, M Ludovica Carerj, Imke Wieters...
https://pubmed.ncbi.nlm.nih.gov/32730619/Actively Recruiting
Led by Johann Wolfgang Goethe University Hospital · Updated on 2026-01-06
6000
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying changes in the magnetic properties of heart muscle tissue caused by disease, which can be detected using T1 and T2 mapping with cardiovascular magnetic resonance CMR. This research aims to establish reliable normal ranges and diagnostic accuracy for these imaging methods across different CMR sequences, vendors, and magnetic field strengths. The study also explores how these measurements relate to clinical factors and cardiovascular risks, including in patients with suspected heart inflammation such as those recently affected by COVID-19 infection or vaccination. Participants will undergo a detailed cardiovascular imaging process including CMR with a contrast agent gadobutrol 0.1 mmolkg to assess tissue mapping, heart volumes, function, strain, and late gadolinium enhancement LGE. Additional assessments include transthoracic echocardiography, blood tests, and cardiopulmonary exercise testing. The study plans to recruit about 3000 subjects, with equal numbers scanned at 1.5 and 3.0 Tesla magnetic field strengths. During the study, participants will be monitored for outcomes such as all-cause mortality at 1 and 5 years, as well as heart failure, cardiovascular, and arrhythmia events over the same periods. The research includes healthy volunteers and those with suspected subclinical heart disease. The findings aim to improve cardiovascular risk assessment using advanced imaging techniques, with long-term follow-up extending to 5 years or more.
CONDITIONS
IMPRoving Cardiovascular RiSk Stratification Using T1 Mapping in General populatION
V
Valentina O Puentmann
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Johann Wolfgang Goethe University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo cardiac imaging including CMR study with contrast agent, transthoracic echocardiography, blood sampling, and cardiopulmonary exercise testing.
1 visit (in-person)
Duration - Up to 5 years
Participants are monitored for cardiovascular outcomes such as mortality, heart failure, cardiovascular events, and arrhythmia over several years.
Visits as needed for outcome assessment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Valentina O Puntmann, M Ludovica Carerj, Imke Wieters...
https://pubmed.ncbi.nlm.nih.gov/32730619/Anastasia Shchendrygina, Mame Madjiguène Ka, Carlos Rodriguez...
https://pubmed.ncbi.nlm.nih.gov/39885199/Valentina O Puntmann, Simon Martin, Anastasia Shchendrygina...
https://pubmed.ncbi.nlm.nih.gov/36064600/Johann Wolfgang Goethe University Hospital
Lead Sponsor